179 related articles for article (PubMed ID: 19222417)
1. Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study.
Labenz J; Armstrong D; Zetterstrand S; Eklund S; Leodolter A
Aliment Pharmacol Ther; 2009 May; 29(9):959-66. PubMed ID: 19222417
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis--results from the maintenance phase of the EXPO study.
Labenz J; Armstrong D; Zetterstrand S; Eklund S; Leodolter A
Aliment Pharmacol Ther; 2009 Jun; 29(11):1165-71. PubMed ID: 19298581
[TBL] [Abstract][Full Text] [Related]
3. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study.
Labenz J; Armstrong D; Lauritsen K; Katelaris P; Schmidt S; Schütze K; Wallner G; Juergens H; Preiksaitis H; Keeling N; Nauclér E; Adler J; Eklund S
Aliment Pharmacol Ther; 2005 Nov; 22(9):803-11. PubMed ID: 16225489
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study.
Goh KL; Benamouzig R; Sander P; Schwan T;
Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):205-11. PubMed ID: 17301646
[TBL] [Abstract][Full Text] [Related]
5. Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
Sharma P; Johnson DA; Monyak JT; Illueca M
Aliment Pharmacol Ther; 2011 Aug; 34(4):487-93. PubMed ID: 21682754
[TBL] [Abstract][Full Text] [Related]
6. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
Bytzer P; van Zanten SV; Mattsson H; Wernersson B
Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg.
Eggleston A; Katelaris PH; Nandurkar S; Thorpe P; Holtmann G;
Aliment Pharmacol Ther; 2009 May; 29(9):967-78. PubMed ID: 19210493
[TBL] [Abstract][Full Text] [Related]
8. Esomeprazole in acute and maintenance treatment of reflux oesophagitis: a multicentre prospective study.
Atug O; Giral A; Kalayci C; Dolar E; Isitan F; Oguz D; Ovunc O; Ozgur O; Soykan I; Simsek I; Unal S; Yenice N;
Adv Ther; 2008 Jun; 25(6):552-66. PubMed ID: 18568450
[TBL] [Abstract][Full Text] [Related]
9. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
[TBL] [Abstract][Full Text] [Related]
10. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.
Castell DO; Kahrilas PJ; Richter JE; Vakil NB; Johnson DA; Zuckerman S; Skammer W; Levine JG
Am J Gastroenterol; 2002 Mar; 97(3):575-83. PubMed ID: 11922549
[TBL] [Abstract][Full Text] [Related]
11. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies.
Laine L; Katz PO; Johnson DA; Ibegbu I; Goldstein MJ; Chou C; Rossiter G; Lu Y
Aliment Pharmacol Ther; 2011 Jan; 33(2):203-12. PubMed ID: 21114792
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis.
Fennerty MB; Johanson JF; Hwang C; Sostek M
Aliment Pharmacol Ther; 2005 Feb; 21(4):455-63. PubMed ID: 15709997
[TBL] [Abstract][Full Text] [Related]
13. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
Armstrong D; Paré P; Pericak D; Pyzyk M;
Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
[TBL] [Abstract][Full Text] [Related]
14. Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study.
Malfertheiner P; Lind T; Willich S; Vieth M; Jaspersen D; Labenz J; Meyer-Sabellek W; Junghard O; Stolte M
Gut; 2005 Jun; 54(6):746-51. PubMed ID: 15888776
[TBL] [Abstract][Full Text] [Related]
15. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study.
Labenz J; Armstrong D; Lauritsen K; Katelaris P; Schmidt S; Schütze K; Wallner G; Juergens H; Preiksaitis H; Keeling N; Nauclér E; Eklund S;
Aliment Pharmacol Ther; 2005 Mar; 21(6):739-46. PubMed ID: 15771760
[TBL] [Abstract][Full Text] [Related]
16. Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status: a double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidine.
Adamek RJ; Behrendt J; Wenzel C
Eur J Gastroenterol Hepatol; 2001 Jul; 13(7):811-7. PubMed ID: 11474311
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study.
Kinoshita Y; Hongo M;
Am J Gastroenterol; 2012 Apr; 107(4):522-30. PubMed ID: 22433921
[TBL] [Abstract][Full Text] [Related]
18. An open non-comparative clinical study for the evaluation of safety and efficacy of esomeprazole in patients of reflux oesophagitis in Indian population.
Dinakaran NH; Rajkumar JS; Potdar NP; Desai A
J Indian Med Assoc; 2002 Oct; 100(10):624-6. PubMed ID: 12452520
[TBL] [Abstract][Full Text] [Related]
19. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis.
Katz PO; Ginsberg GG; Hoyle PE; Sostek MB; Monyak JT; Silberg DG
Aliment Pharmacol Ther; 2007 Mar; 25(5):617-28. PubMed ID: 17305763
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial: esomeprazole for moderate-to-severe nighttime heartburn and gastro-oesophageal reflux disease-related sleep disturbances.
Johnson D; Crawley JA; Hwang C; Brown K
Aliment Pharmacol Ther; 2010 Jul; 32(2):182-90. PubMed ID: 20456306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
